ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025

FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation.

Ashley C Woods et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.